AngioDynamics, with its disruptive and innovative medical devices, addresses unmet patient needs by elevating the standard of care for chronic and acute disease states in vascular, peripheral vascular, and oncology medicine.
These devices provide healthcare professionals around the world with the vital tools they need to deliver high-quality patient care and improve patient outcomes.
Each day, AngioDynamics and its employees earn the trust of patients and the medical community by being a committed partner that continuously focuses on delivering safer, clinically-relevant and economically-favorable solutions that help improve patient outcomes.
AngioDynamics Reports Fiscal 2019 Second Quarter Financial Results
AngioDynamics to Present at the J.P. Morgan Healthcare Conference
European Vascular Course
Date: 10 Mar, 2019
Time:
Location: MECC Maastricht, Netherlands
AngioDynamics to Report Fiscal 2019 Second Quarter Financial Results on January 4, 2019
AngioDynamics Reports Fiscal 2019 First Quarter Financial Results
Fiscal 2019 Second Quarter HighlightsNet sales of $91.5 million, an increase of 5.5% year over yearGross margin expanded 440 basis points year over year to 53.7%GAAP EPS of $0.06 per ...
AngioDynamics® history is best characterized by innovation and growth. Originally founded in Queensbury, N.Y., U.S., in 1988, AngioDynamics has grown into a NASDAQ-listed public company with a global reach.
USA
International